Subscribe
shutterstock_547487782_fabioberti
fabioberti / Shutterstock.com
12 February 2019Asia

Pharma group asks USTR to drop India from watch list

The lobby group for India’s pharma industry has asked the  US Trade Representative (USTR) office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.

More on this story

Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?